Receptor News and Research

RSS

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

CXCL12 protein can inhibit metastasis of colon and melanoma cancers

Researchers at the Medical College of Wisconsin have shown that a protein can inhibit metastasis of colon and melanoma cancers. The findings are published in the October 10, 2011 issue of Proceedings of the National Academy of Sciences.

11 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions.

10 Oct 2011

Researchers show how nuclear receptors battle each other during fruit fly metamorphosis

Growing up just got more complicated. Thomas Jefferson University biochemistry researchers have shown for the first time that the receptor for a major insect molting hormone doesn't activate and repress genes as once thought. In fact, it only activates genes, and it is out-competed by a heme-binding receptor to repress the same genes during the larval to pupal transition in the fruit fly.

7 Oct 2011

NCKU research team discovers potential target to treat osteoporosis

A National Cheng Kung University (NCKU) research team has discovered that a protein called interleukin (IL)-20 is a key to treating osteoporosis, a disease that lowers a person's bone density.

7 Oct 2011

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.

7 Oct 2011

Scientists discover new metabolic pathway which makes gliomas more aggressive

A research alliance of Heidelberg University Hospital and the German Cancer Research Center, jointly with colleagues of the Helmholtz Center for Environmental Research in Leipzig, have discovered a new metabolic pathway which makes malignant brain tumors (gliomas) more aggressive and weakens patients' immune systems.

7 Oct 2011

Researchers identify gene responsible for aggressive, bold behavior in zebrafish

A gene responsible for aggressive and bold behavior has been identified in zebrafish by a team from CNRS/Laboratoire Neurobiologie et Développement.

7 Oct 2011

Lipomannan on TB bacterium's outer cell surface can block TNF production

The bacterium that causes tuberculosis has a unique molecule on its outer cell surface that blocks a key part of the body's defense. New research suggests this represents a novel mechanism in the microbe's evolving efforts to remain hidden from the human immune system.

4 Oct 2011

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

AMRI announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla.

4 Oct 2011

Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director.

3 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011

Researchers determine structure of RIG-I protein linked with viral infections

Researchers at Rutgers and UMDNJ-Robert Wood Johnson Medical School have determined the structure of a protein that is the first line of defense in fighting viral infections including influenza, hepatitis C, West Nile, rabies, and measles.

30 Sep 2011

Resveratrol inhibits proliferation of hormone resistant breast cancer cells

Cheers! A new research report appearing in the October 2011 issue of The FASEB Journal shows that resveratrol, the "healthy" ingredient in red wine, stops breast cancer cells from growing by blocking the growth effects of estrogen.

30 Sep 2011

Immune cells in brain linked with behavioural responses to alcohol

University of Adelaide researchers have found that immune cells in your brain may contribute to how you respond to alcohol.

30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011

Immune cells in brain may predict alcohol abuse effects

Adelaide University researchers say there's a growing body of evidence that alcohol triggers rapid changes in the immune system in the brain and this is behind responses like staggering and slurring. They claim that blocking part of the immune system might reduce alcohol abuse and help prevent drink driving accidents.

29 Sep 2011

Receptor News and Research

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

CXCL12 protein can inhibit metastasis of colon and melanoma cancers

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Researchers show how nuclear receptors battle each other during fruit fly metamorphosis

NCKU research team discovers potential target to treat osteoporosis

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

Scientists discover new metabolic pathway which makes gliomas more aggressive

Researchers identify gene responsible for aggressive, bold behavior in zebrafish

Lipomannan on TB bacterium's outer cell surface can block TNF production

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

Adaptimmune announces new board appointments as clinical programmes get underway

La Jolla Institute scientist identifies previously unknown T cell interaction

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

Researchers determine structure of RIG-I protein linked with viral infections

Resveratrol inhibits proliferation of hormone resistant breast cancer cells

Immune cells in brain linked with behavioural responses to alcohol

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Immune cells in brain may predict alcohol abuse effects

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News